Beyfortus approved in China to protect infants from RSV; Illumina investor files class action suit

AstraZeneca and Sanofi’s Beyfortus won an approval in China to prevent RSV lower respiratory tract infection in newborns and infants during their first RSV season. US regulators approved the monoclonal antibody for the same indication in July, and the White House laid out…
Click here to view original post

Advertisement — Advertise with Biotech Networks